News, Syndication, Xconomy »

Cebix Raises $16M From Investors
Posted by Mary Canady September 1st, 2010 .
No Comments

San Diego-based Cebix, which is developing a replacement therapy based on human proinsulin C-peptide as a suppemental treatment for complications from type 1 diabetes, has raised $16 million over the...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

Innovators in Boston, San Diego, San Francisco, Seattle Top World Economic Forum’s List of Technology Pioneers
Posted by Mary Canady September 1st, 2010 .
No Comments

The World Economic Forum—the body behind the exclusive annual gathering in Davos, Switzerland—today released its “Technology Pioneers” list for 2011. An unusually large number...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

Will the Stem Cell Ruling Affect Venture Capital Investing?
Posted by Mary Canady September 1st, 2010 .
No Comments

Last week’s federal district court ruling ordering an immediate halt in federal funding for stem cell research has thrown academic research circles into a state of confusion. This has caught...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

San Diego’s ReVision Therapeutics, Founded in April, Takes on Development of Drug Candidate for Age-Related Blindness
Posted by Mary Canady August 31st, 2010 .
No Comments

A San Diego biopharmaceutical startup, formed just five months ago to resume development of a compound for treating age-related macular degeneration, has reported encouraging results from a two-year,...

[[Click headline to continue reading.]] More...

BioSpace, News, Syndication »

Allergan Inc. Resolves United States Government Investigation of Past Sales and Marketing Practices Relating to Certain Therapeutic Uses of BOTOX(R)’ to Pay $375 Million to Government, Plus Another $225 In Civil Claims
Posted by BioSpace.com Featured News August 31st, 2010 .
No Comments

IRVINE, Calif., Sep 01, 2010 (BUSINESS WIRE) -- Allergan, Inc. /quotes/comstock/13*!agn/quotes/nls/agn (AGN 61.42, -0.59, -0.95%) today announced that it has reached a resolution with the United States Department of Justice (DOJ) regarding the previously reported Government investigation into Allergan's past U.S. sales and marketing practices relating to certain therapeutic uses of BOTOX(R) (onabotulinumtoxinA... More...

BioSpace, News, Syndication »

Allergan Inc. Receives FDA Approval for LUMIGAN(R) 0.01% as First-Line Therapy Indicated for the Reduction of Elevated Intraocular Pressure in Glaucoma Patients
Posted by BioSpace.com Featured News August 31st, 2010 .
No Comments

IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc. (NYSE:AGN - News) today announced the United States Food and Drug Administration (FDA) has approved LUMIGAN (bimatoprost ophthalmic solution) 0.01% as a first-line therapy indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. LUMIGAN 0.01% is an optimized reformulation of LUMIGAN... More...

BioSpace, News, Syndication »

Allergan Inc. To Pay $600 Mln To Settle Botox Probe
Posted by BioSpace.com Featured News August 31st, 2010 .
No Comments

IRVINE, Calif., Sep 01, 2010 (BUSINESS WIRE) -- Allergan, Inc. /quotes/comstock/13*!agn/quotes/nls/agn (AGN 61.42, -0.59, -0.95%) today announced that it has reached a resolution with the United States Department of Justice (DOJ) regarding the previously reported Government investigation into Allergan's past U.S. sales and marketing practices relating to certain therapeutic uses of BOTOX(R) (onabotulinumtoxinA... More...

BioSpace, News, Syndication »

Genzyme Corporation Release: Data from Mipomersen Phase 3 Trial in heFH Patients Presented at European Society of Cardiology
Posted by BioSpace.com Featured News August 31st, 2010 .
No Comments

CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) announced that data from the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) were presented today at the European Society of Cardiologys Congress 2010 in Stockholm, Sweden. The study met its primary endpoint with a 28 percent... More...

BioSpace, News, Syndication »

ReVision’s Fenretinide (RT-101) Reduced Incidence of Choroidal Neovascularization by More Than 50 Percent in Patients With Geographic Atrophy in a Phase 2b Trial
Posted by BioSpace.com Featured News August 31st, 2010 .
No Comments

SAN DIEGO, Sept. 1 /PRNewswire/ -- ReVision Therapeutics Inc. today announced that data from a Phase 2b trial show that fenretinide (RT-101) reduced the incidence of choroidal neovascularization (CNV, wet age related macular degeneration) by about 50 percent in patients with geographic atrophy (GA), the most advanced form of dry age related macular degeneration... More...